English Journal
- Leucomycin A3, a 16-membered macrolide antibiotic, inhibits influenza A virus infection and disease progression.
- Sugamata R1, Sugawara A2, Nagao T1, Suzuki K3, Hirose T2, Yamamoto KI4, Oshima M4, Kobayashi K4, Sunazuka T2, Akagawa KS5, Omura S2, Nakayama T6, Suzuki K1.Author information 11] Inflammation Program, Graduate School of Medicine, Chiba University, Chiba City, Japan [2] Department of Immunology, National Institute of Infectious Diseases, Shinjuku-ku, Japan.2The Kitasato Institute, Kitasato Institute for Life Sciences and Graduate School of Infection Control Sciences, Kitasato University, Minato-ku, Japan.3Inflammation Program, Graduate School of Medicine, Chiba University, Chiba City, Japan.4Department of Immunology, National Institute of Infectious Diseases, Shinjuku-ku, Japan.51] Department of Immunology, National Institute of Infectious Diseases, Shinjuku-ku, Japan [2] The Kitasato Institute, Kitasato Institute for Life Sciences and Graduate School of Infection Control Sciences, Kitasato University, Minato-ku, Japan.6Department of Immunology, Graduate School of Medicine, Chiba University, Chiba City, Japan.AbstractSevere respiratory disease arising from influenza virus infection has a high fatality rate. Neutrophil myeloperoxidase (MPO) has been implicated in the pathogenesis of severe influenza-induced pneumonia because extracellularly released MPO mediates the production of hypochlorous acid, a potent tissue injury factor. To search for candidate anti-influenza compounds, we screened leucomycin A3 (LM-A3), spiramycin (SPM), an erythromycin derivative (EM900, in which anti-bacterial activity has been eliminated), and clarithromycin (CAM), by analyzing their ability to inhibit MPO release in neutrophils from mice and humans. When each candidate was injected into mice infected with a lethal dose of A/H1N1 influenza virus (PR-8), LM-A3 produced the highest survival rate (80.9%). We found that LM-A3 induced beneficial effects on lung pathology and viral proliferation involved in the regulatory activity of MPO release, pro-inflammatory cytokines and interferon-α production in the lung. SPM and EM900 also induced positive survival effects in the infected mice, whereas CAM did not. We further found that these compounds inhibit virus proliferation in human pneumonia epithelial A549 cells in vitro. LM-A3 showed effective action against influenza A virus infection with high anti-viral activity in human host cells, indicating the possibility that LM-A3 is a prospective lead compound for the development of a drug for human influenza. The positive survival effect induced by EM900 suggests that pharmacological architectures between anti-bacterial and anti-influenza virus activities can be dissociated in macrolide derivatives. These observations provide valuable evidence for the potential development of novel macrolide derivatives that have strong anti-viral but no anti-bacterial activity.The Journal of Antibiotics advance online publication, 5 February 2014; doi:10.1038/ja.2013.132.
- The Journal of antibiotics.J Antibiot (Tokyo).2014 Feb 5. doi: 10.1038/ja.2013.132. [Epub ahead of print]
- Severe respiratory disease arising from influenza virus infection has a high fatality rate. Neutrophil myeloperoxidase (MPO) has been implicated in the pathogenesis of severe influenza-induced pneumonia because extracellularly released MPO mediates the production of hypochlorous acid, a potent tissu
- PMID 24496145
- Decline in extractable kitasamycin during the composting of kitasamycin manufacturing waste with dairy manure and sawdust.
- Ding N1, Li W2, Liu C1, Fu Q1, Guo B3, Li H1, Li N1, Lin Y1.Author information 1Institute of Environment, Resource, Soil and Fertilizer, Zhejiang Academy of Agricultural Sciences, Hangzhou, China.2Department of Science, Qianjiang College of Hangzhou Normal University, Hangzhou 310012, China.3Institute of Environment, Resource, Soil and Fertilizer, Zhejiang Academy of Agricultural Sciences, Hangzhou, China. Electronic address: ndgb@163.com.AbstractThe aim of this study was to propose a feasible treatment of kitasamycin manufacturing waste by examining extractable kitasamycin and evaluating its compost maturity during the composting of waste with different ratios of dairy manure and sawdust over a 40-day period (volume/volume/volume; M1, 0/80/20; M2, 10/70/20; and M3, 30/50/20). During composting, the concentration of extractable kitasamycin in kitasamycin-contaminated composts declined rapidly, and was undetectable in M2 within 15 days. M2 also achieved the highest fertility compost, which was characterised by the following final parameters: electrical conductivity, 2.34 dS cm-1; pH, 8.15; total C/N, 22.2; water-soluble NH4+, P, and K, 0.37, 3.43, and 1.05 g kg-1, respectively; and plant germination index values, 92%. Furthermore, DGGE analysis showed a dramatic increase in the diversity of bacterial species during composting. In contrast, a high concentration (121 mg kg-1) of extractable kitasamycin still remained in the M3 compost, which exerted an inhibitory effect on the composting, resulting in reduced bacterial diversity, high values of electrical conductivity and water-soluble NH4+, a low C/N ratio, and a low plant germination index value. Furthermore, 3.86 log (CFU g-1) kitasamycin-resistant bacteria were still present on day 40, indicating the biological degradation contributed to the decline of extractable kitasamycin.
- Journal of environmental management.J Environ Manage.2014 Jan 23;134C:39-46. doi: 10.1016/j.jenvman.2013.12.030. [Epub ahead of print]
- The aim of this study was to propose a feasible treatment of kitasamycin manufacturing waste by examining extractable kitasamycin and evaluating its compost maturity during the composting of waste with different ratios of dairy manure and sawdust over a 40-day period (volume/volume/volume; M1, 0/80/
- PMID 24463847
- SmeOP-TolCsm Efflux Pump Contributes to the Multidrug Resistance of Stenotrophomonas maltophilia.
- Lin CW, Huang YW, Hu RM, Yang TC.Author information Department of Medical Laboratory Science and Biotechnology, China Medical University, Taichung 404, Taiwan.AbstractA five-gene cluster, tolCsm-pcm-smeRo-smeO-smeP, of Stenotrophomonas maltophilia was characterized. The presence of smeOP and smeRo-pcm-tolCsm operons was verified by RT-PCR. Both operons were negatively regulated by the TetR-type transcriptional regulator SmeRo, as demonstrated by quantitative-RT-PCR and promoter-fusion assay. SmeO and SmeP were associated with TolCsm for assembly of a RND-type pump. The compounds extruded by SmeOP-TolCsm mainly included nalidixic acid, doxycycline, amikacin, gentamicin, erythromycin, leucomycin, carbonyl cyanide 3-chlorophenylhydrazone, crystal violet, sodium dodecyl sulfate, and tetrachlorosalicylanilide.
- Antimicrobial agents and chemotherapy.Antimicrob Agents Chemother.2014 Jan 6. [Epub ahead of print]
- A five-gene cluster, tolCsm-pcm-smeRo-smeO-smeP, of Stenotrophomonas maltophilia was characterized. The presence of smeOP and smeRo-pcm-tolCsm operons was verified by RT-PCR. Both operons were negatively regulated by the TetR-type transcriptional regulator SmeRo, as demonstrated by quantitative-RT-P
- PMID 24395237
Japanese Journal
- Novel Azalides Derived from Sixteen-Membered Macrolides : I. Isolation of the Mobile Dialdehyde and Its One-Pot Macrocyclization with an Amine
- MIURA Tomoaki,NATSUME Satomi,KANEMOTO Kenichi,ATSUMI Kunio,FUSHIMI Hideki,SASAI Hiroaki,ARAI Takayoshi,YOSHIDA Takuji,AJITO Keiichi
- Journal of antibiotics = An International Journal Devoted to Research on Bioactive Microbial Products 60(7), 407-435, 2007-07-25
- NAID 10019831258
- マクロライド系薬の新作用と創薬
- 砂塚 敏明
- 日本化学療法学会雑誌 52(7), 367-370, 2004
- エリスロマイシン (EM) を代表とするマクロライド系抗菌薬は, ブドウ球菌, 連鎖球菌, 肺炎球菌などのグラム場性菌, 淋菌, コレラ菌などの一部のグラム陰性菌およびマイコプラズマに対して抗菌活性を示し, 臨床的にきわめて毒性の低い抗菌薬として広く用いられている。<BR>最近になって, 新たな作川として消化管運動機能尤進作用が注目され, 消化管ホルモンであるモチリンのアゴニストである …
- NAID 130004102697
- Synthesis and Biological Evaluation of Novel Leucomycin Analogues Modified at the C-3 Position I. Epimerization and Methylation of the 3-Hydroxyl Group
- FURUUCHI TAKESHI,KURIHARA KEN-ICHI,YOSHIDA TAKUJI,AJITO KEIICHI
- Journal of antibiotics 56(4), 399-414, 2003-04-25
- NAID 10011436752
Related Links
- ロイコマイシン【leucomycin】とは。意味や解説。扁桃(へんとう)炎・肺炎などの感染症の治療に用いるマクロライド系抗生物質。キタサマイシン。 - goo辞書は国語、英和、和英、中国語、百科事典等からまとめて探せる辞書検索 ...
- Find quality suppliers and manufacturers of Leucomycinfor price inquiry.where to buy Leucomycin.Also offer free database of Leucomycin including MSDS sheet(poisoning, toxicity, hazards and safety),chemical properties,Formula ...
Related Pictures
